News & Updates

Nivolumab plus chemo offers prolonged survival in resectable NSCLC
Nivolumab plus chemo offers prolonged survival in resectable NSCLC
14 Jun 2024 byStephen Padilla

Patients with resectable nonsmall cell lung cancer (NSCLC) enjoy sustained survival from neoadjuvant nivolumab when added to chemotherapy compared with chemotherapy alone, as seen in the 4-year analysis from the phase III CheckMate 816 study.

Nivolumab plus chemo offers prolonged survival in resectable NSCLC
14 Jun 2024
Blood-based CRC screening platform delivers promising performance
Blood-based CRC screening platform delivers promising performance
13 Jun 2024